• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

VEGFR-targeted ultrasound may improve detection of pancreatic cancer

byXiaofan PanandAaron Maxwell, MD
October 19, 2014
in Gastroenterology, Imaging and Intervention, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Ultrasound with a vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted contrast agent allowed for noninvasive detection of pancreatic ductal adenocarcinoma (PDAC) in a transgenic mice model.

2. The degree of enhancement with VEGFR2-targeted contrast was significantly higher in PDAC lesions as compared to normal pancreatic tissue.

Evidence Rating Level: 3 (Average)       

Study Rundown: Pancreatic ductal adenocarcinoma is a highly aggressive cancer that is often diagnosed at an advanced stage. Multiple approaches to screening with diagnostic imaging have been previously been attempted with unfavorable results, and new strategies that allow for early detection are needed. Targeted contrast-enhanced ultrasound (US) is an emerging imaging technique that combines standard US technology with molecularly-targeted contrast agents to assess biological processes such as angiogenesis.  Angiogenesis, the growth of new blood vessels, plays a critical role in the development of tumors and metastases, making it an attractive target for both cancer imaging and therapy. VEGFR2 is considered a key molecular marker of tumor angiogenesis and it is overexpressed in several cancers, including PDAC. The goal of the present study was to investigate the utility of VEGFR2-targeted US in PDAC detection. A transgenic mouse model of PDAC was used, and VEGFR2-targeted microbubbles (MB) were employed as an US contrast material. Researchers found that the microbubbles preferentially targeted PDAC cells while sparing normal pancreatic tissue, resulting in significantly higher signal intensities by US in PDAC mice than in control mice. Size was found to be important in PDAC visibility, with smaller tumors appearing more conspicuous than larger tumors. These results represent a major step forward for pancreatic cancer screening, but further studies in humans are needed to definitively support the use of VEGFR2-based imaging among PDAC patients.

Click to read the study in Radiology

Relevant Reading: Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging

In-Depth [animal study]: Forty-four transgenic mice bred for early PDAC development were studied using US after intravenous injection of VEGFR2 -targeted microbubble contrast. Sixty-four wild-type mice with no evidence of PDAC  underwent the same protocol and served as healthy controls. Following contrast-enhanced US, pancreatic tissue was harvested from both PDAC and control mice and analyzed with hematoxylin-eosin staining and immunostaining for VEGFR2 expression. Ultrasound signal intensity was found to be 26.8-fold higher in transgenic mice harboring PDAC lesions than in healthy, wild type mice (P < .001). VEGFR2-mediated signal intensity varied with PDAC lesion size; tumors  less than 3 mm in diameter demonstrated a 30.8-fold higher signal intensity than control tissue (P < .001), while lesions greater than 3 mm in diameter had only 1.7-fold higher signal intensity. Histologic evaluation confirmed significantly higher VEGFR2 expression in pancreatic tumors as compared with healthy, wild-type pancreatic tissue, supporting the specificity of VEGFR2-targeted microbubbles in PDAC lesion identification.

RELATED REPORTS

Preoperative biliary draining prior to pancreaticoduodenectomy not associated with increased complication risk

Polycystic ovarian syndrome is associated with an increased risk of pancreatic cancer

#VisualAbstract: Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer

More from this author: Cryoablation safe and effective for pain control in sternal metastases, Cardiac MRI predicts degree of heart dysfunction after STEMI, Ultrasound useful for risk stratification after nondiagnostic thyroid biopsy, Mammography linked to improved breast cancer outcomes among women 75 and older, Regional central nervous damage associated with fatigue in multiple sclerosis

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: pancreatic cancerultrasound
Previous Post

MR lymphangiography useful for evaluation of central lymphatic pathology

Next Post

Severe psoriasis linked with poorly controlled blood pressure

RelatedReports

Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine
Gastroenterology

Preoperative biliary draining prior to pancreaticoduodenectomy not associated with increased complication risk

November 25, 2022
VEGFR-targeted ultrasound may improve detection of pancreatic cancer
Oncology

Polycystic ovarian syndrome is associated with an increased risk of pancreatic cancer

October 17, 2022
#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
StudyGraphics

#VisualAbstract: Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer

September 29, 2022
Screening insufficient for newborns exposed to hepatitis C virus
Chronic Disease

Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance

September 19, 2022
Next Post
Severe psoriasis linked with poorly controlled blood pressure

Severe psoriasis linked with poorly controlled blood pressure

Incidence of esophageal cancer subtypes vary drastically globally and by gender

Incidence of esophageal cancer subtypes vary drastically globally and by gender

Parents desensitized with increasing exposure to movie violence/sex

Parents desensitized with increasing exposure to movie violence/sex

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options